STIM Neuronetics

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.

"We are delighted to be extending our commercial relationship with TCN, a long-standing, valued customer with a commitment to providing the best care for their patients," said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics. "With the continued increase in the need for mental health services, we're glad that NeuroStar TMS is a significant part of TCN's plan to grow and strengthen mental healthcare in their communities."

With an extensive network of facilities strategically located across six states and an ambitious roadmap for further expansion, TCN's comprehensive five-year exclusive agreement with Neuronetics stands as a pivotal advancement in broadening patient access to innovative NeuroStar TMS treatments. This is particularly significant in the context of addressing major depressive disorder (MDD), including treatment-resistant depression (TRD), a condition that presents substantial challenges in mental health care due to the complexity and difficulty in achieving remission with conventional treatments.

"Transformations Care Network's alliance with NeuroStar is more than a milestone; it is a tangible manifestation of our vision to integrate the most advanced treatments in our suite of services," said Brian Wheelan, Chief Executive Officer at Transformations Care Network. "This collaboration will empower our teams across the network to deliver exceptional care with even greater efficacy, reinforcing our pledge to provide access to the best possible mental health solutions."

NeuroStar TMS therapy offers a beacon of hope for individuals grappling with MDD, providing a non-invasive, FDA-cleared treatment that has demonstrated efficacy in cases where traditional pharmacological interventions have failed. By integrating NeuroStar TMS into its array of mental health services, TCN not only elevates the standard of care available to patients but also embodies a forward-thinking approach to mental health treatment. This initiative underscores a commitment to embracing advanced technologies and treatments that can make a meaningful difference in the lives of those affected by some of the most intractable forms of depression.

To learn more about NeuroStar® Advanced Therapy, visit . To learn more about Transformations Care Network, visit .

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.1 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, .

About Transformations Care Network

Transformations Care Network (“TCN”) stands as a vanguard in the provision of comprehensive outpatient mental health care services across the nation. With a network that spans multiple states and embraces a myriad of individualized brands, including Northeast Health Services in Massachusetts, New Directions Mental Health in Pennsylvania, Harmony in West Virginia, Columbia Associates in the DMV area, and LightHeart Associates in Washington, TCN's commitment to community-integrated, accessible mental health care is unwavering. Our services, tailored for a diverse clientele ranging from children aged five to adults, encompass a wide range of outpatient mental health care solutions.

Central to our ethos is the belief in rapid access to quality care and the relentless pursuit of innovation in mental health care strategies. Our facilities, deeply woven into the fabric of their respective communities, offer both in-person and telehealth services, ensuring that comprehensive care is within reach for everyone. As a payor-agnostic entity, we proudly accept a broad spectrum of insurance providers, including Medicaid, Medicare, Tricare, and a vast array of commercial insurances. This approach, coupled with our dedicated central intake teams in each market, facilitates a seamless connection to the vital care our clients deserve.

Media Contact:

EvolveMKD

646.517.4220

 



EN
07/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE

Neuronetics to Report First Quarter 2024 Financial and Operating Resul...

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conf...

 PRESS RELEASE

New Publication in Brain Stimulation Confirms Full TMS Treatment Cours...

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital Lack of early symptom improvement is not predictive of final responder status MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced  of significant clinical findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, the premier journal in the field of neuromodulatio...

 PRESS RELEASE

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these aw...

 PRESS RELEASE

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add...

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an ad...

 PRESS RELEASE

Neuronetics Announces 5-Year Exclusive Partnership with Transformation...

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch